

## **R5 AND EMULTECH ANNOUNCE COLLABORATION**

Leading formulation development specialist R5 and EmulTech, a specialist contract development organisation focusing on Advanced Drug Delivery Systems, have announced a collaborative partnership.

As both businesses operate in niche formulation development fields, the strategic partnership will provide a unified platform from which they can expand more rapidly, while enhancing their bespoke service provision.

R5 develops and manufactures new medicines and clinical trial materials and is widely acknowledged as one of the leading providers of pharmaceutical dosage form development across Europe. It provides market leading formulation development, analytics and GMP services and guides clients through the processes of new medicine and material development for Phase I and Phase II clinical trials, maximising budget effectiveness by minimising experimentation without sacrificing quality levels.

R5 was acquired by leading pharmaceutical manufacturer, Aesica, in June 2010 and now forms one of Aesica's three business units; R5 Formulation Development, Active Pharmaceutical Ingredients and Formulated Products.

EmulTech develops drug delivery systems using its superior microparticulate technology. This proprietary Emulsion Technology for Micro Encapsulates (ET4ME) is a highly versatile process, providing solutions to many current market demands, including uniformity, and reproducibility issues. The company is able to quickly test various formulations, requiring only small volumes and its parallel scale up strategy allows for swift and reproducible scale up. Throughout the product development cycle EmulTech also provides both product and process development support enabling clients to experience added value at all stages.

The collaboration of both organisations will enhance productivity, provide increased value to the client and enable shorter development times.

Paul Titley, Managing Director, R5 Formulation Development says: "Since we were acquired by Aesica in 2010 we have been able to reach new markets more quickly and enhance our service offering significantly.

Working with EmulTech will further enhance our credibility and we hope to create a long-term strategic partnership that enables us to innovate within the formulation development arena and consolidate our respective businesses. We believe our collaboration with EmulTech and the combination of our early stage research and development expertise and its advanced drug delivery capability, will add a new and invaluable dimension to the Aesica business model and provide added value to our global clients.”

Fränk de Jong, CEO, EmulTech adds: “We are looking forward to the collaboration with R5, as we are both niche providers to the global pharmaceutical and biotechnology industries. The uniformity and reproducibility of the products that we develop through our process will seamlessly integrate in the cGMP workflow of R5. As a result, our customers will experience increased value, an enhanced service and leaner development times, all of which are essential qualities in the current marketplace.”

Aesica is a leading full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.

Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within Aesica enables it to provide primary and secondary contract manufacturing services to the highest possible regulatory standards. It is this full-service offer, its dedication to exceptional standards of service and its ability to deliver innovation and added value for its clients that truly sets Aesica apart from its counterparts.

For details about Aesica please visit [www.aesica-pharma.com](http://www.aesica-pharma.com) and for details about EmulTech please visit [www.EmulTech.nl](http://www.EmulTech.nl)